

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

03 Jul 2026

### The effect of dexmedetomidine on hemodynamic changes in patients undergoing coronary artery bypass graft

#### Protocol summary

##### Study aim

The effect of dexmedetomidine on hemodynamic changes in patients undergoing coronary artery bypass graft (CABG)

##### Design

Phase-II randomized controlled trial, with parallel groups; without blinding; on 72 patients, randomization with sealed envelopes

##### Settings and conduct

This randomized controlled trial will include 72 candidates of elective coronary bypass graft (CABG) with cardiopulmonary bypass (CPB) in Payambar Azam Hospital, Bandar Abbas. Patients will randomly be allocated to two groups. In the dexmedetomidine group, 0.5 mcg/kg of the drug will be injected intravenously within 10 min. The control group will not receive dexmedetomidine. Hemodynamic parameters, including systolic and diastolic blood pressure, mean arterial pressure, heart rate, systemic vascular resistance, central venous pressure, and cardiac output will be measured and recorded at different time points in both groups. Also, pump time and aortic clamp time will be recorded for all patients. Inotrope requirement and its administered dose will also be noted for all patients.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Age 30-80 year; American Society of Anesthesiologists (ASA) class II, III, and IV; Candidates of elective coronary artery bypass graft (CABG) with cardiopulmonary bypass (CPB). Exclusion criteria: Emergency surgery; Ejection fraction <30%; Concurrent valvular surgery; Any complication during surgery and pacemaker requirement.

##### Intervention groups

Intervention group: A 0.5 mcg/kg dose of dexmedetomidine will be injected intravenously within 10 min before anesthesia induction. Control group: Anesthesia induction without dexmedetomidine injection.

##### Main outcome variables

Blood pressure

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20220316054311N1**

Registration date: **2022-03-24, 1401/01/04**

Registration timing: **registered\_while\_recruiting**

Last update: **2022-03-24, 1401/01/04**

Update count: **0**

##### Registration date

2022-03-24, 1401/01/04

##### Registrant information

##### Name

Seyed Mohammad Abtahi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 76 3334 5009

##### Email address

abtahi\_mohamad@yahoo.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-12-22, 1400/10/01

##### Expected recruitment end date

2022-04-04, 1401/01/15

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

The effect of dexmedetomidine on hemodynamic changes in patients undergoing coronary artery bypass graft

#### Public title

The effect of dexmedetomidine on hemodynamic changes in patients undergoing coronary artery bypass graft

#### Purpose

Treatment

#### Inclusion/Exclusion criteria

##### Inclusion criteria:

Age 30-80 years American Society of Anesthesiologists (ASA) class II, III, and IV Candidates of elective coronary artery bypass graft (CABG) with cardiopulmonary bypass (CPB)

##### Exclusion criteria:

Emergency surgery Ejection fraction <30% Concurrent valvular surgery Any complication during surgery and pacemaker requirement

#### Age

From **30 years** old to **80 years** old

#### Gender

Both

#### Phase

3

#### Groups that have been masked

*No information*

#### Sample size

Target sample size: **72**

#### Randomization (investigator's opinion)

Randomized

#### Randomization description

Simple randomization with individuals as units of randomization along with allocation concealment: 72 unclear envelopes and 72 cards with the names of the groups (A, B) will be prepared (36 cards for each group). The cards will be put into the envelopes and the envelopes will be sealed and provided to the investigator. Upon entrance of each patient to the study, the envelopes will be shuffled and one will randomly be selected. The patient will be allocated to group A or B based on the card inside the selected envelope.

#### Blinding (investigator's opinion)

Not blinded

#### Blinding description

##### Placebo

Not used

##### Assignment

Parallel

#### Other design features

### Secondary Ids

empty

### Ethics committees

#### 1

##### Ethics committee

Name of ethics committee

Ethics Committee of Hormozgan University of Medical Sciences

#### Street address

Imam Hossein Blvd., across from Kargaran Sports Complex, Faculty of Medicine

#### City

Bandar Abbas

#### Province

Hormozgan

#### Postal code

7916613885

#### Approval date

2021-07-05, 1400/04/14

#### Ethics committee reference number

IR.HUMS.REC.1400.132

### Health conditions studied

#### 1

##### Description of health condition studied

coronary artery bypass graft

##### ICD-10 code

I25.709

##### ICD-10 code description

Atherosclerosis of coronary artery bypass graft(s), unspecified, with unspecified angina pectoris

### Primary outcomes

#### 1

##### Description

Blood pressure

##### Timepoint

Baseline, before sternotomy, immediately after sternotomy and then at 10, 20, 30, 40, 50, and 60 min, before CPB, before cross clamp removal, before weaning, after weaning, before sternal closure, after sternal closure, at 1, 2, 3, 4, 5, and 6 hour in the intensive care unit

##### Method of measurement

Monitoring device

### Secondary outcomes

#### 1

##### Description

Mean arterial pressure

##### Timepoint

Baseline, before sternotomy, immediately after sternotomy and then at 10, 20, 30, 40, 50, and 60 min, before CPB, before cross clamp removal, before weaning, after weaning, before sternal closure, after sternal closure, at 1, 2, 3, 4, 5, and 6 hour in the intensive care unit

##### Method of measurement

Monitoring device

## 2

### **Description**

Systemic vascular resistance

### **Timepoint**

Baseline, before sternotomy, immediately after sternotomy and then at 10, 20, 30, 40, 50, and 60 min, before CPB, before cross clamp removal, before weaning, after weaning, before sternal closure, after sternal closure, at 1, 2, 3, 4, 5, and 6 hour in the intensive care unit

### **Method of measurement**

Monitoring device

## 3

### **Description**

Cardiac output

### **Timepoint**

Baseline, before sternotomy, immediately after sternotomy and then at 10, 20, 30, 40, 50, and 60 min, before CPB, before cross clamp removal, before weaning, after weaning, before sternal closure, after sternal closure, at 1, 2, 3, 4, 5, and 6 hour in the intensive care unit

### **Method of measurement**

Monitoring device

## 4

### **Description**

Heart rate

### **Timepoint**

Baseline, before sternotomy, immediately after sternotomy and then at 10, 20, 30, 40, 50, and 60 min, before CPB, before cross clamp removal, before weaning, after weaning, before sternal closure, after sternal closure, at 1, 2, 3, 4, 5, and 6 hour in the intensive care unit

### **Method of measurement**

Monitoring device

## 5

### **Description**

Central venous pressure

### **Timepoint**

Baseline, before sternotomy, immediately after sternotomy and then at 10, 20, 30, 40, 50, and 60 min, before CPB, before cross clamp removal, before weaning, after weaning, before sternal closure, after sternal closure, at 1, 2, 3, 4, 5, and 6 hour in the intensive care unit

### **Method of measurement**

Monitoring device

## 6

### **Description**

Cross clamp time

### **Timepoint**

During surgery

### **Method of measurement**

Clinical assessment

## 7

### **Description**

Pump time

### **Timepoint**

During surgery

### **Method of measurement**

Clinical assessment

## 8

### **Description**

Inotrope requirement

### **Timepoint**

During surgery

### **Method of measurement**

Clinical assessment

## **Intervention groups**

### 1

#### **Description**

Intervention group: In the dexmedetomidine group, one dose of the drug at 0.5 mcg/kg will be injected intravenously within 10 min.

#### **Category**

Treatment - Drugs

### 2

#### **Description**

Control group: They will receive no dexmedetomidine.

#### **Category**

Other

## **Recruitment centers**

### 1

#### **Recruitment center**

##### **Name of recruitment center**

Payambar Azam Hospital

##### **Full name of responsible person**

Seyed Mohammad Abtahi

##### **Street address**

Jomhoury Eslami Blvd., Payambar Azam Hospital

##### **City**

Bandar Abbas

##### **Province**

Hormozgan

##### **Postal code**

9791991551

##### **Phone**

+98 76 3334 7000

##### **Fax**

+98 76 3334 5003

##### **Email**

shmh@hums.ac.ir

##### **Web page address**

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Vice-Chancellery for Research Hormozgan University of Medical Sciences

**Full name of responsible person**

Teamur Aghamolaei

**Street address**

Imam Hossein Blvd., across from Kargaran Sports Complex

**City**

Bandar Abbas

**Province**

Hormozgan

**Postal code**

7919693116

**Phone**

+98 76 3371 0393

**Email**

teaghamolaei@gmail.com

**Web page address**

<https://resv.hums.ac.ir/>

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Vice-Chancellery for Research Hormozgan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact****Name of organization / entity**

Bandare-abbas University of Medical Sciences

**Full name of responsible person**

Seyed Mohammad Abtahi

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Anesthesiology

**Street address**

Jomhouri Eslami Blvd., Payambar Azam Hospital

**City**

Bandar Abbas

**Province**

Hormozgan

**Postal code**

9791991551

**Phone**

+98 76 3334 5009

**Email**

abtahi\_mohamad@yahoo.com

## Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Bandare-abbas University of Medical Sciences

**Full name of responsible person**

Seyed Mohammad Abtahi

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Anesthesiology

**Street address**

Jomhouri Eslami Blvd., Payambar Azam Hospital

**City**

Bandar Abbas

**Province**

Hormozgan

**Postal code**

9791991551

**Phone**

+98 76 3334 5009

**Email**

abtahi\_mohamad@yahoo.com

## Person responsible for updating data

**Contact****Name of organization / entity**

Bandare-abbas University of Medical Sciences

**Full name of responsible person**

Seyed Mohammad Abtahi

**Position**

Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Anesthesiology

**Street address**

Jomhouri Eslami Blvd., Payambar Azam Hospital

**City**

Bandar Abbas

**Province**

Hormozgan

**Postal code**

9791991551

**Phone**

+98 76 3334 5009

**Email**

## **Sharing plan**

### **Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

### **Justification/reason for indecision/not sharing IPD**

There is no further information.

### **Study Protocol**

No - There is not a plan to make this available

### **Statistical Analysis Plan**

No - There is not a plan to make this available

### **Informed Consent Form**

No - There is not a plan to make this available

### **Clinical Study Report**

No - There is not a plan to make this available

### **Analytic Code**

No - There is not a plan to make this available

### **Data Dictionary**

No - There is not a plan to make this available